July 26, 2022
(press release)
–
West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, has recently released its 2021 Corporate Responsibility Report, reporting on the Company's environmental, social, and governance (ESG) performance in 2021. This is West's 6th annual CR Report, and highlights ESG successes from over the past year, including progress on environmental sustainability goals, diversity and inclusion, and success around the Company's philanthropic efforts. It also highlights some of the recognition received for its ESG performance, including placement in Barron's Top 100 Most Sustainable Companies, Corporate Social Responsibility Programme of the Year from Pharma Industry Awards in Ireland, and a Silver Stevie Award for Corporate Social Responsibility. "At West, we are driven by our purpose to improve patient lives. We know that to fulfill this purpose effectively, we must consider our broader corporate responsibilities to the wide range of stakeholders we serve," said Eric M. Green, President, Chief Executive Officer and Chair of the Board. "Much of our long-term success can be credited to our focus on building a diverse team, putting quality at center stage, operating with integrity, giving back to our communities, managing our environmental footprint, and caring for the health and safety of our team members – all of these combined makes for a better performing company now and into the future." Some of the key 2021 highlights include: In addition to the CR Report, West also provides transparency in disclosure through alignment with the United Nations Sustainable Development Goals, the Sustainability Accounting Standards Board (SASB) Index, and the Task Force on Climate-Related Financial Disclosures (TCFD). Please read the full CR Report here to learn more about West's commitment to ESG. About West Headquartered in Exton, Pennsylvania, and in business for nearly a century, West in its fiscal year 2021 generated $2.83 billion in net sales. West is traded on the New York Stock Exchange (NYSE: WST) and is included on the Standard & Poor's 500 index. For more information, visit www.westpharma.com. All trademarks and registered trademarks used in this release are the property of West Pharmaceutical Services, Inc. or its subsidiaries, in the United States and other jurisdictions, unless otherwise noted. SOURCE West Pharmaceutical Services, Inc. Media Contact: Eric Haman, Director, Global Corporate Communications, +1-215-873-3772, Eric.Haman@westpharma.com or Investor Relations Contact: Quintin Lai, +1-610-594-3318, Quintin.Lai@westpharma.com
West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With approximately 10,000 team members across 50 sites worldwide, West helps support our customers by delivering over 45 billion components and devices each year.
* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.
